<DOC>
	<DOCNO>NCT01052610</DOCNO>
	<brief_summary>The purpose trial ass efficacy safety sublingual annual immunotherapy child bronchial asthma and/or allergic rhinitis allergic house dust mite .</brief_summary>
	<brief_title>Assessment Sublingual Immunotherapy Children Allergic House Dust Mites</brief_title>
	<detailed_description>Allergen immunotherapy currently one method cause treatment IgE-dependent allergic disease . Sublingual immunotherapy ( SLIT ) method allow give allergen via alternative oral route patient home . Due possibility avoid injection therapy offer well relationship pediatric patient . However efficacy safety sublingual immunotherapy still important issue , especially asthmatic child . The purpose trial ass efficacy safety sublingual annual immunotherapy child bronchial asthma and/or allergic rhinitis allergic house dust mite .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>patient bronchial asthma and/or allergic rhinitis allergic house dust mite first diagnose least 2 year study active respiratory tract infection require antibiotic treatment within 4 week study hospitalisation due asthma exacerbation 3 month first visit know contraindication SIT accord EAACI previous allergen immunotherapy use systemic corticosteroid clinically significant pulmonary , hematologic , hepatic , gastrointestinal , renal , endocrine , neurologic , cardiovascular , and/or mental disease malignancy either put patient risk participate study could influence result study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>SLIT</keyword>
	<keyword>bronchial asthma</keyword>
	<keyword>allergic rhinitis</keyword>
</DOC>